Ranibizumab for the treatment of diabetic macular oedema

NICE technology appraisals [TA237] Published date:

1 Guidance

1 Guidance

1.1 Ranibizumab is not recommended for the treatment of visual impairment due to diabetic macular oedema.

1.2 People currently receiving ranibizumab for the treatment of visual impairment due to diabetic macular oedema should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce technology appraisals guidance. Accreditation is valid for 5 years from September 2009 and applies to guidance produced since June 2008 using the processes described in NICE's 'The guide to the methods of technology appraisal' (2008). More information on accreditation can be viewed at www.nice.org.uk/accreditation
Get involved